BamatNAEkhaguereOAZhangL, et al. Protocol adherence rates in superiority and non-inferiority randomized clinical trials published in high-impact medical journals. Clin Trials2020.
2.
TwelvesCWongANowackiMP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med2005; 352: 2696–2704.
3.
SaadEDBuyseM. Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects. Acta Oncol2012; 51(7): 890–896.
4.
Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), U.S. Department of Health and Human Services. Non-inferiority clinical trials to establish effectiveness: guidance for industry, https://www.fda.gov/media/78504/download (2016, accessed 2 June 2020).
5.
PiaggioGElbourneDRAltmanDG, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA2006; 295: 1152–1160.
6.
MotzerRJHutsonTEReevesJ, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. 2012 ESMO Congress. Abstract LBA8. https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2820%2934325-8 (2012, accessed 9 June 2020).
